About Us
We seek to lead investments in life science companies which have, or can develop, the following attributes:
• World leading technology with thorough patent protection which is based on excellent science.
• Technology with potential for multiple applications.
• An Entrepreneur, A leader and or experienced management team.
• Significant international market opportunities.
• A foreseeable and coherent business model with a commercialization plan.
• Potential for high ROI coupled with an identifiable exit mechanism.
• Therapeutic or device opportunities from product focused companies at the clinic (or near).
We are not afraid to roll up our sleeves, work with the entrepreneur or management through technical details. Business plans, IP and regulatory strategies and other processes on the road to success.
Invtch provides funding from the early stages of company initiation and technology proof of concept to later stage investment. We specialize (and really love...) in incubating ideas. There is nothing like the feeling of working with inventor to capture his idea and transform it to a viable success story.
When we consider start-ups who develop new medicines we seek transforming therapies rather than "best in class". The medicine should be at the clinic or close to it with a known action mechanism and path to registration. We seek to ensure that the financing strategy is aligned with key development stages such as IND filing, phase I trials and phase II efficacy trials.
Australia is the leading location of biotechnology and life science companies in Asia- Pacific with almost 450 biotechnology companies and 600 medical technology companies. The majority of these companies is in human therapeutics and is supported by world-class research organizations. Currently there are 111 ASX-listed life science companies.
A 2009 survey of listed Australian Bio-tech companies indicated that there were 63 clinical trials underway, 13 of which were Phase III and 30 phase II. According to E&Y latest report - beyond borders global Biotechnology report 2011. Australia's biotech investment has shown some significant acquisition (ChemGenex by Cephalon for 240$ million and Celestis by Qiagen for 360$ million) and some partnerships with global companies. On the other hand it still remains hard for younger companies to gain capital through investments following the global economic downturn.
For further information on the life science venture capital arena in Australia and around the world please check the following links:
